TScan Therapeutics, Inc.

Name: TScan Therapeutics, Inc. standardized financial statements, quarterly
Creator: Listed

TCRXNasdaqCIK 1783328HealthcareFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$1.1m, Q2 FY2026

Operating income−$30.5m, Q2 FY2026

Net income−$30.4m, Q2 FY2026

TScan Therapeutics, Inc., income statement, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Revenue	$m	3.9	7.2	0.6	0.5	1.0	0.7	2.2	3.1	2.5	2.6	1.0	1.1
Research and development	$m	22.7	22.4	24.9	26.9	26.3	29.4	29.8	32.6	31.7	20.0	21.9	23.4
Operating income	$m	(24.7)	(21.4)	(31.4)	(34.1)	(32.6)	(36.7)	(36.3)	(38.7)	(37.1)	(23.9)	(29.1)	(30.5)
Interest expense	$m	1.0	0.9	1.0	1.0	1.0	0.8	0.7	0.7	0.7	0.7	0.7	0.7
Net income	$m	(23.0)	(19.6)	(30.1)	(31.7)	(29.9)	(35.8)	(34.1)	(37.0)	(35.7)	(23.0)	(28.7)	(30.4)
Diluted EPS	$ per share	(0.24)	not reported	(0.32)	(0.28)	(0.25)	not reported	(0.26)	(0.28)	(0.28)	not reported	(0.22)	(0.23)
Basic EPS	$ per share	(0.24)	not reported	(0.32)	(0.28)	(0.25)	not reported	(0.26)	(0.28)	(0.28)	not reported	(0.22)	(0.23)

Balance sheet

Cash and equivalents$100.2m, Q2 FY2026

Long-term debt$21.1m, Q2 FY2026

Shareholders' equity$69.0m, Q2 FY2026

TScan Therapeutics, Inc., balance sheet, quarterly
Line item	Unit	Q3 FY20232023-09-30	FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Cash and equivalents	$m	155	133	141	242	133	179	154	169	170	152	128	100
Current assets	$m	218	194	165	300	274	293	255	221	188	157	133	104
Total assets	$m	291	272	241	375	348	371	333	299	262	229	202	171
Current liabilities	$m	33.2	29.8	31.5	38.6	28.7	36.0	29.8	31.3	29.2	18.7	20.0	31.0
Total liabilities	$m	122	121	118	120	119	130	123	122	118	106	105	102
Long-term debt	$m	28.8	26.7	23.4	20.1	30.6	32.1	32.2	32.3	32.4	32.5	32.7	21.1
Current portion of debt	$m	1.1	3.3	6.8	10.3	not reported	not reported	not reported	not reported	not reported	not reported	not reported	11.7
Shareholders' equity	$m	169	151	123	255	229	241	210	177	144	123	96.9	69.0

Cash flow

Operating cash flow−$27.5m, Q2 FY2026

Capital expenditure$493.0k, Q2 FY2026

TScan Therapeutics, Inc., cash flow, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Operating cash flow	$m	8.0	(23.8)	(29.3)	(26.2)	(27.9)	(27.4)	(37.6)	(33.3)	(32.5)	(32.0)	(24.3)	(27.5)
Capital expenditure	$m	1.4	0.5	0.7	0.9	1.4	0.9	1.5	1.3	1.4	0.2	0.1	0.5

Diluted shares (weighted)129.95m, Q2 FY2026

TScan Therapeutics, Inc., shares, quarterly
Line item	Unit	Q3 FY20222022-09-30	Q1 FY20232023-03-31	Q2 FY20232023-06-30	Q3 FY20232023-09-30	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Diluted shares (weighted)	m shares	24.1	24.2	47.2	94.8	94.9	113	119	130	130	130	130	130

Shares outstanding: 23.98m at Mar 4, 2022, from the cover of the 10-K filed Mar 9, 2022.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:47 ET. Listed shows no prices and gives no investment advice.